Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential

Authors:   J.W. Hopewell,T. Gorlia,L. Pellettieri,V. Giusti,B. H-Stenstam,K. Sköld,
Journal: Applied Radiation and Isotopes
https://doi.org/10.1016/j.apradiso.2011.03.022
Abstract: The purpose of this analysis was to assess the potential of BNCT, with l-boronophenylalanine (l-BPA), as first line radiotherapy for glioblastoma multiforme (GBM). The survival of patients with newly diagnosed GBM from a phase II BNCT study was compared with those from the two arms of a phase III study with conventional radiotherapy (RT) vs. RT plus concomitant and adjuvant medication with temozolomide (TMZ). A small subgroup, for which the methylation status of the O6-methylguanine–DNA methyltransferase (MGMT) DNA-repair gene was known, was also considered. The results indicated that the use of BNCT with BPA should be explored in a stratified randomized phase II trial in which patients with the unmethylated MGMT DNA-repair gene are offered BNCT vs. RT plus TMZ.